Developer docs
API playgroundTry for free, no card

Search company profiles

Ncardia

Full company profile

uuid0000m3y

Namestring
Ncardia
Legal namestring
Ncardia Services B.V.
Websiteurl
ncardia.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Ncardia Services B.V. is a Netherlands-based biotechnology company operating a human induced pluripotent stem cell (iPSC) platform that supports drug discovery, disease modeling and preclinical safety assessment for biopharmaceutical and biotechnology customers. Founded in 2011 as Pluriomics and rebranded to Ncardia in 2017, the company is headquartered in Leiden with operations spanning Europe and North America, and is majority-owned by U.S. investment platform Kiniciti following a $60 million strategic investment in 2021.

The company's core technology stack rests on three pillars: proprietary STAR-CRISPR gene editing, which delivers roughly 90% knock-out efficiency and 2-3x higher knock-in efficiency than standard CRISPR methods with reduced off-target effects in iPSCs; a large-scale bioreactor manufacturing platform capable of producing 1 to over 10 billion cells per batch with batch-to-batch reproducibility designed to anchor 3-5 year screening programs; and a catalog of human iPSC-derived cell products under the Ncyte brand spanning ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells and 3D cardiac microtissues (Heart in a Box), complemented by advanced research series offerings such as hematopoietic, lung progenitor and alveolar type II cells. These are paired with custom services including 12-week iPSC reprogramming, gene editing and differentiation, and an integrated iPSC-based assay platform (ready-to-use assays plus custom screening) with applications across cardiovascular, neuroscience, immuno-oncology and regenerative medicine programs.

Ncardia generates revenue through three streams: catalog sales of off-the-shelf Ncyte cell products via its website, custom iPSC services (reprogramming, gene editing, differentiation) priced on a quote basis, and drug discovery assay services including the multi-tissue IO Safety Panel for immuno-oncology. Distribution is direct, with global shipping and direct sales engagement for enterprise pharmaceutical clients and academic research institutions. The company is affiliated with Cellistic, a 2022 spin-out focused on GMP iPSC-based cell therapy manufacturing that capitalizes on Ncardia's differentiation processes. Leadership under CEO Jason Conner (previously Kiniciti, Patheon/Thermo Fisher) and CTO/co-founder Stefan Braam links the firm to academic founders Prof. Dr. Mummery and Prof. Dr. Passier.

Short descriptiontext

Ncardia is a Netherlands-based iPSC technology company that provides human induced pluripotent stem cell-derived cell products, custom reprogramming and gene editing services, and assay platforms to biopharmaceutical, biotechnology, cell therapy and academic customers for drug discovery, disease modeling and preclinical safety assessment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC cell products, drug discovery services, stem cell technology, cell-based assays, biopharmaceutical research
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
iPSC Drug Discovery Services & Cell Models
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1iPSC Cell Products (Catalog)
TypeOne Time License
Description

Sale of off-the-shelf iPSC-derived cell products including ventricular cardiomyocytes (Ncyte vCardiomyocytes), atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells, and 3D cardiac microtissues (Ncyte Heart in a Box). Products are cryopreserved cells sold in various formats with or without culture media.

ncardia.com
2Custom iPSC Services
TypeProfessional Services
Description

Custom services including iPSC reprogramming (12-week delivery), gene editing using STAR-CRISPR technology, and differentiation into specific cell types. Services are project-based with custom specifications.

ncardia.com
3Drug Discovery Assay Services
TypeProfessional Services
Description

iPSC-based assay services for efficacy and safety screening including ready-to-use assays (cardiotoxicity, neurotoxicity, angiogenesis, etc.) and custom screening campaigns. Supports various therapeutic modalities including small molecules, biologics, RNA therapeutics, and gene therapy.

ncardia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Off-the-shelf cell products sold individually or as kits with culture media
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard shipping costs: 1750.00 EUR per kit for Europe, Asia, North America; 3500.00 EUR for Canada, Mexico, Puerto Rico and other regions with additional import requirements.

ncardia.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ncardia operates an iPSC technology platform that produces and sells standardized, off-the-shelf human iPSC-derived cell products (including ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells, 3D cardiac microtissues, and non-human primate cardiomyocytes) alongside custom iPSC services — reprogramming, proprietary STAR-CRISPR gene editing, large-scale differentiation and iPSC-based assay/screening services for drug discovery, disease modeling, and safety/toxicology assessment. Customers are biopharmaceutical companies, biotechnology companies, cell therapy developers and academic research institutions that need physiologically relevant human cell models for preclinical research and therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Deliveries of multi-billion-cell batches supporting 3-5 years of consistent assay performance from a single batch
+2 more records
Product overview1 text field

Ncardia is an iPSC technology company providing a comprehensive platform of human iPSC-derived cell products and discovery services. The core offering includes the Ncyte® product line of standardized, off-the-shelf cell models (ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells) and 3D cardiac microtissues (Heart in a Box™), complemented by custom services (reprogramming, STAR-CRISPR gene editing, differentiation) and assay platforms (ready-to-use and custom screening). The portfolio spans cardiovascular, neural, and vascular cell types for drug discovery, disease modeling, and toxicology applications, with the proprietary IO Safety Panel enabling multi-tissue safety assessment in a single workflow.

Product and service16 records
1Ncyte® vCardiomyocytes
CategoryiPSC cell product
Description

Human iPSC-derived ventricular cardiomyocytes providing physiologically relevant and fully functional cells for cardiac drug discovery, toxicity testing, and disease modeling applications, sold as off-the-shelf cryopreserved cell products to biopharmaceutical and biotech researchers.

2Ncyte® aCardiomyocytes
CategoryiPSC cell product
Description

Human iPSC-derived atrial cardiomyocytes for studying atrial-specific cardiac biology and drug effects on atrial tissue, supplied as off-the-shelf cell products to researchers in cardiovascular drug discovery.

3Ncyte® Endothelial Cells
CategoryiPSC cell product
Description

Human iPSC-derived vascular endothelial cells for vascular biology research, angiogenesis studies and endothelial barrier function assessments, sold as off-the-shelf cryopreserved cell products.

4Ncyte® Heart in A Box™
CategoryiPSC 3D tissue product
Description

Human iPSC-derived 3D cardiac microtissue model providing more physiologically relevant cardiac tissue for drug discovery and toxicity screening, sold as an off-the-shelf 3D tissue product.

5Ncyte® Plate-Ready vCardiomyocytes
CategoryiPSC cell product
Description

Human iPSC-derived plate-ready ventricular-like cardiomyocytes providing a convenient, time-saving solution for a wide range of cardiac functional assays with reliable and reproducible results.

6Ncyte® NHP-C vCardiomyocytes
CategoryiPSC cell product
Description

Non-Human Primate (cynomolgus monkey) iPSC-derived ventricular-like cardiomyocytes enabling cross-species cardiac research and more ethical preclinical safety studies; positioned as the only iPSC-derived NHP ventricular cardiomyocytes on the market.

7Ncyte® Astrocytes
CategoryiPSC cell product
Description

Human iPSC-derived astrocytes for neurobiology research, neurotoxicity assessments, and neurological disease modeling, sold as off-the-shelf cryopreserved cell products.

8Ncyte® Microglia
CategoryiPSC cell product
Description

Human iPSC-derived microglia for neuroinflammation research, neurodegeneration studies and CNS drug discovery applications, launched in 2025 as a catalog cell product.

9Ncyte® Smooth Muscle Cells
CategoryiPSC cell product
Description

Human iPSC-derived vascular smooth muscle cells for vascular research and smooth muscle-related disease modeling, supplied as off-the-shelf cryopreserved cell products.

10Advanced Research Series Cell Products (Hematopoietic Stem Cells, Lung Progenitor Cells, Alveolar Type II Cells, 8M Vials)
CategoryiPSC cell product (advanced research)
Description

Specialty iPSC cell products including high-purity hematopoietic stem/progenitor cells (≥70% CD34+/CD45+/CD43+), lung progenitor cells (≥70% CPM+/NKX2.1+), alveolar type II epithelial cells (≥70% Pro-SPC+/ABCA3+), and high-cell-density ventricular cardiomyocyte vials (≥8M viable cells/vial) for advanced research, disease modeling and large-scale screening.

11iPSC Reprogramming Services
CategoryCustom iPSC service
Description

Custom reprogramming services transforming patient- or donor-specific somatic cells (human, mouse and primate sources) into high-quality induced pluripotent stem cells, with delivery in as little as 12 weeks and 100+ lines reprogrammed to date.

12STAR-CRISPR Gene Editing Service
CategoryCustom iPSC service
Description

Custom gene editing service using Ncardia's proprietary STAR-CRISPR technology, delivering ~90% knock-out efficiency and knock-in efficiency 2–3× higher than other methods, with minimal off-target editing for disease modeling and target validation in iPSCs.

13iPSC Differentiation Services
CategoryCustom iPSC service
Description

Scalable differentiation procedures using 2D and 3D stirred-tank bioreactor platforms, producing functional cell types at volumes needed for high-throughput screening, preclinical cell therapy, and tissue engineering, with batch sizes from 1 to more than 10 billion cells.

14iPSC-Based Assay Services
CategoryDrug discovery assay service
Description

Custom and ready-to-use iPSC-based assay services for drug efficacy and safety evaluation, supporting small molecules, biologics, RNA therapeutics, and gene therapy modalities across multiple therapeutic areas.

15Ncyte® IO Safety Panel
CategoryDrug discovery assay service
Description

Human iPSC-based multi-tissue safety screening service evaluating functional toxicity (via real-time impedance monitoring) across seven human iPSC-derived tissues — neurons, cardiomyocytes, endothelial cells, melanocytes, hepatocytes, intestinal epithelial cells, and alveolar epithelial cells — in a single integrated workflow designed for immuno-oncology and multi-modality safety programs.

16Ready-to-Use iPSC Assays
CategoryDrug discovery assay service
Description

Standardized ready-to-use iPSC-based assay panels covering angiogenesis, biomarker detection, calcium transients, cell painting, contractility, electrophysiology, endothelial barrier function, high content imaging, and metabolism assays for drug efficacy and safety evaluation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Researchers at LUMC in the Netherlands developed an automated platform using stem cell-derived 3D cardiac microtissues to accelerate cardiac drug discovery in collaboration with Ncardia. The platform combines robotics and machine learning and was used to screen over 2,000 FDA-approved compounds, identifying approximately 100 that corrected abnormal heart rhythms in a catecholaminergic polymorphic ventricular tachycardia model. The collaboration bridges academic research and industrial drug development.

2Cellistic
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cellistic is an affiliate company formed in 2022 focused on iPSC-based cell therapy manufacturing. The company capitalizes on Ncardia's large-scale manufacturing expertise and proven processes in iPSC differentiation. Ncardia can transfer processes to Cellistic for GMP manufacturing of cell therapy products. Both companies share leadership, with Jason Conner serving as CEO of both Cellistic and Ncardia.

ncardia.com
Strategic tierCoreTypeTechnology or Integration
Description

Ncardia holds a non-exclusive license agreement for iPSC technology from iPS Academia Japan Inc., which represents Kyoto University (where Shinya Yamanaka's original iPSC discovery was made). This license allows Ncardia to commercialize products derived from human induced pluripotent stem cells.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

FUJIFILM Cellular Dynamics is the most direct competitor: an iPSC pioneer founded out of Jamie Thomson's lab, offering a comprehensive catalog of iPSC-derived cells (cardiomyocytes, neurons, hepatocytes, etc.) and custom iPSC services. Both companies target the same biopharma preclinical customer with off-the-shelf cell products and drug discovery assay services.

TypeDirect peer
Description

Evotec is a leading global CRO with established iPSC-based drug discovery platforms (e.g., its PanHunter screening and iPSC-derived disease modeling services). Comparable to Ncardia in offering integrated iPSC-based discovery services to large pharma, but at materially greater scale and with broader therapeutic area coverage.

TypeBroad incumbent
Description

Charles River is a top-3 global CRO with growing iPSC and cell-based assay capabilities across safety, discovery, and manufacturing services. Ncardia's Divisional CEO Jeroen de Groot was previously COO Early Discovery at Charles River, illustrating direct talent and capability overlap. Competes for the same enterprise pharma RFPs.

TypeBroad incumbent
Description

Lonza is a global CDMO with significant cell and gene therapy manufacturing capabilities plus iPSC-related services. As the most established cell therapy CDMO, it represents the scaled incumbent that Cellistic (Ncardia's affiliate) is positioning against in the GMP iPSC manufacturing space.

TypeBroad incumbent
Description

Thermo Fisher, via its Patheon acquisition (where Ncardia CEO Jason Conner previously held leadership), operates a global pharma services network including biologics and cell therapy capabilities. Represents the largest scaled competitor that combines CDMO scale with pharma services relationships.

TypeEmerging player
Description

bit.bio is an emerging UK-based iPSC platform company offering opti-ox™-engineered iPSC-derived cell products for research and therapeutic applications. Direct competitor in iPSC cell products, particularly neural and immune cell types, with novel reprogramming technology.

TypeRegional player
Description

CST's Cell signaling portfolio includes high-quality iPSC-derived cell products and reagents. Comparable in catalog cell product offering, with stronger footprint in US academic and pharma research customers versus Ncardia's European-anchored presence.

TypeEmerging player
Description

Axol Bioscience is an emerging UK-based iPSC-derived cell product company specializing in neural and cardiac cell types. Direct catalog overlap with Ncardia's Ncyte® neural cells, though smaller in scale and primarily serving academic and early-stage biotech customers.

TypeEmerging player
Description

Pluristyx is an emerging iPSC technology company offering iPSC banking, gene editing, and differentiation services. Direct peer in custom iPSC services, particularly for cell therapy developers, with comparable focus on supporting translational programs.

TypeEmerging player
Description

ReproCELL is a Japan-based iPSC-derived cell product and services company with strong ties to Kyoto University/Yamanaka's iPSC ecosystem — same licensor as Ncardia. Direct competitor in iPSC catalog products, particularly strong in Asia-Pacific where Ncardia's reach is more limited.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ncardia

iPSC Drug Discovery Services & Cell Modelsncardia.com

Ncardia is a Netherlands-based iPSC technology company that provides human induced pluripotent stem cell-derived cell products, custom reprogramming and gene editing services, and assay platforms to biopharmaceutical, biotechnology, cell therapy and academic customers for drug discovery, disease modeling and preclinical safety assessment.

What Ncardia does

Ncardia Services B.V. is a Netherlands-based biotechnology company operating a human induced pluripotent stem cell (iPSC) platform that supports drug discovery, disease modeling and preclinical safety assessment for biopharmaceutical and biotechnology customers. Founded in 2011 as Pluriomics and rebranded to Ncardia in 2017, the company is headquartered in Leiden with operations spanning Europe and North America, and is majority-owned by U.S. investment platform Kiniciti following a $60 million strategic investment in 2021.

The company's core technology stack rests on three pillars: proprietary STAR-CRISPR gene editing, which delivers roughly 90% knock-out efficiency and 2-3x higher knock-in efficiency than standard CRISPR methods with reduced off-target effects in iPSCs; a large-scale bioreactor manufacturing platform capable of producing 1 to over 10 billion cells per batch with batch-to-batch reproducibility designed to anchor 3-5 year screening programs; and a catalog of human iPSC-derived cell products under the Ncyte brand spanning ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells and 3D cardiac microtissues (Heart in a Box), complemented by advanced research series offerings such as hematopoietic, lung progenitor and alveolar type II cells. These are paired with custom services including 12-week iPSC reprogramming, gene editing and differentiation, and an integrated iPSC-based assay platform (ready-to-use assays plus custom screening) with applications across cardiovascular, neuroscience, immuno-oncology and regenerative medicine programs.

Ncardia generates revenue through three streams: catalog sales of off-the-shelf Ncyte cell products via its website, custom iPSC services (reprogramming, gene editing, differentiation) priced on a quote basis, and drug discovery assay services including the multi-tissue IO Safety Panel for immuno-oncology. Distribution is direct, with global shipping and direct sales engagement for enterprise pharmaceutical clients and academic research institutions. The company is affiliated with Cellistic, a 2022 spin-out focused on GMP iPSC-based cell therapy manufacturing that capitalizes on Ncardia's differentiation processes. Leadership under CEO Jason Conner (previously Kiniciti, Patheon/Thermo Fisher) and CTO/co-founder Stefan Braam links the firm to academic founders Prof. Dr. Mummery and Prof. Dr. Passier.

Ncardia firmographics

Firmographics
Name
Ncardia
Legal name
Ncardia Services B.V.
Website
https://ncardia.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Ncardia is a Netherlands-based iPSC technology company that provides human induced pluripotent stem cell-derived cell products, custom reprogramming and gene editing services, and assay platforms to biopharmaceutical, biotechnology, cell therapy and academic customers for drug discovery, disease modeling and preclinical safety assessment.
Ownership category
akta.pro rank

Ncardia industry classification

Industry
Product category
iPSC Drug Discovery Services & Cell Models
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • IPSC cell products
  • Drug discovery services
  • Stem cell technology
  • Cell-based assays
  • Biopharmaceutical research

Where Ncardia is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Ncardia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. iPSC Cell Products (Catalog): Sale of off-the-shelf iPSC-derived cell products including ventricular cardiomyocytes (Ncyte vCardiomyocytes), atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells, and 3D cardiac microtissues (Ncyte Heart in a Box). Products are cryopreserved cells sold in various formats with or without culture media.
  2. Custom iPSC Services: Custom services including iPSC reprogramming (12-week delivery), gene editing using STAR-CRISPR technology, and differentiation into specific cell types. Services are project-based with custom specifications.
  3. Drug Discovery Assay Services: iPSC-based assay services for efficacy and safety screening including ready-to-use assays (cardiotoxicity, neurotoxicity, angiogenesis, etc.) and custom screening campaigns. Supports various therapeutic modalities including small molecules, biologics, RNA therapeutics, and gene therapy.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOff-the-shelf cell products sold individually or as kits with culture media

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Ncardia product offering

Product offering

Core offering

Ncardia operates an iPSC technology platform that produces and sells standardized, off-the-shelf human iPSC-derived cell products (including ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells, 3D cardiac microtissues, and non-human primate cardiomyocytes) alongside custom iPSC services — reprogramming, proprietary STAR-CRISPR gene editing, large-scale differentiation and iPSC-based assay/screening services for drug discovery, disease modeling, and safety/toxicology assessment. Customers are biopharmaceutical companies, biotechnology companies, cell therapy developers and academic research institutions that need physiologically relevant human cell models for preclinical research and therapeutic development.

Product overview

Ncardia is an iPSC technology company providing a comprehensive platform of human iPSC-derived cell products and discovery services. The core offering includes the Ncyte® product line of standardized, off-the-shelf cell models (ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells) and 3D cardiac microtissues (Heart in a Box™), complemented by custom services (reprogramming, STAR-CRISPR gene editing, differentiation) and assay platforms (ready-to-use and custom screening). The portfolio spans cardiovascular, neural, and vascular cell types for drug discovery, disease modeling, and toxicology applications, with the proprietary IO Safety Panel enabling multi-tissue safety assessment in a single workflow.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ncyte® vCardiomyocytes Human iPSC-derived ventricular cardiomyocytes providing physiologically relevant and fully functional cells for cardiac drug discovery, toxicity testing, and disease modeling applications, sold as off-the-shelf cryopreserved cell products to biopharmaceutical and biotech researchers.
  • Ncyte® aCardiomyocytes Human iPSC-derived atrial cardiomyocytes for studying atrial-specific cardiac biology and drug effects on atrial tissue, supplied as off-the-shelf cell products to researchers in cardiovascular drug discovery.
  • Ncyte® Endothelial Cells Human iPSC-derived vascular endothelial cells for vascular biology research, angiogenesis studies and endothelial barrier function assessments, sold as off-the-shelf cryopreserved cell products.
  • Ncyte® Heart in A Box™ Human iPSC-derived 3D cardiac microtissue model providing more physiologically relevant cardiac tissue for drug discovery and toxicity screening, sold as an off-the-shelf 3D tissue product.
  • Ncyte® Plate-Ready vCardiomyocytes Human iPSC-derived plate-ready ventricular-like cardiomyocytes providing a convenient, time-saving solution for a wide range of cardiac functional assays with reliable and reproducible results.
  • Ncyte® NHP-C vCardiomyocytes Non-Human Primate (cynomolgus monkey) iPSC-derived ventricular-like cardiomyocytes enabling cross-species cardiac research and more ethical preclinical safety studies; positioned as the only iPSC-derived NHP ventricular cardiomyocytes on the market.
  • Ncyte® Astrocytes Human iPSC-derived astrocytes for neurobiology research, neurotoxicity assessments, and neurological disease modeling, sold as off-the-shelf cryopreserved cell products.
  • Ncyte® Microglia Human iPSC-derived microglia for neuroinflammation research, neurodegeneration studies and CNS drug discovery applications, launched in 2025 as a catalog cell product.
  • Ncyte® Smooth Muscle Cells Human iPSC-derived vascular smooth muscle cells for vascular research and smooth muscle-related disease modeling, supplied as off-the-shelf cryopreserved cell products.
  • Advanced Research Series Cell Products (Hematopoietic Stem Cells, Lung Progenitor Cells, Alveolar Type II Cells, 8M Vials) Specialty iPSC cell products including high-purity hematopoietic stem/progenitor cells (≥70% CD34+/CD45+/CD43+), lung progenitor cells (≥70% CPM+/NKX2.1+), alveolar type II epithelial cells (≥70% Pro-SPC+/ABCA3+), and high-cell-density ventricular cardiomyocyte vials (≥8M viable cells/vial) for advanced research, disease modeling and large-scale screening.
  • iPSC Reprogramming Services Custom reprogramming services transforming patient- or donor-specific somatic cells (human, mouse and primate sources) into high-quality induced pluripotent stem cells, with delivery in as little as 12 weeks and 100+ lines reprogrammed to date.
  • STAR-CRISPR Gene Editing Service Custom gene editing service using Ncardia's proprietary STAR-CRISPR technology, delivering ~90% knock-out efficiency and knock-in efficiency 2–3× higher than other methods, with minimal off-target editing for disease modeling and target validation in iPSCs.
  • iPSC Differentiation Services Scalable differentiation procedures using 2D and 3D stirred-tank bioreactor platforms, producing functional cell types at volumes needed for high-throughput screening, preclinical cell therapy, and tissue engineering, with batch sizes from 1 to more than 10 billion cells.
  • iPSC-Based Assay Services Custom and ready-to-use iPSC-based assay services for drug efficacy and safety evaluation, supporting small molecules, biologics, RNA therapeutics, and gene therapy modalities across multiple therapeutic areas.
  • Ncyte® IO Safety Panel Human iPSC-based multi-tissue safety screening service evaluating functional toxicity (via real-time impedance monitoring) across seven human iPSC-derived tissues — neurons, cardiomyocytes, endothelial cells, melanocytes, hepatocytes, intestinal epithelial cells, and alveolar epithelial cells — in a single integrated workflow designed for immuno-oncology and multi-modality safety programs.
  • Ready-to-Use iPSC Assays Standardized ready-to-use iPSC-based assay panels covering angiogenesis, biomarker detection, calcium transients, cell painting, contractility, electrophysiology, endothelial barrier function, high content imaging, and metabolism assays for drug efficacy and safety evaluation.

Quantifiable outcome

  • Deliveries of multi-billion-cell batches supporting 3-5 years of consistent assay performance from a single batch
  • +2 more outcomes

Companies that use Ncardia

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Ncardia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Ncardia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Leiden University Medical Center (LUMC)coreStrategic or Co-development PartnerResearchers at LUMC in the Netherlands developed an automated platform using stem cell-derived 3D cardiac microtissues to accelerate cardiac drug discovery in collaboration with Ncardia. The platform combines robotics and machine learning and was used to screen over 2,000 FDA-approved compounds, identifying approximately 100 that corrected abnormal heart rhythms in a catecholaminergic polymorphic ventricular tachycardia model. The collaboration bridges academic research and industrial drug development.
  • CellisticcoreStrategic or Co-development PartnerCellistic is an affiliate company formed in 2022 focused on iPSC-based cell therapy manufacturing. The company capitalizes on Ncardia's large-scale manufacturing expertise and proven processes in iPSC differentiation. Ncardia can transfer processes to Cellistic for GMP manufacturing of cell therapy products. Both companies share leadership, with Jason Conner serving as CEO of both Cellistic and Ncardia.
  • iPS Academia Japan Inc. (on behalf of Kyoto University)coreTechnology or IntegrationNcardia holds a non-exclusive license agreement for iPSC technology from iPS Academia Japan Inc., which represents Kyoto University (where Shinya Yamanaka's original iPSC discovery was made). This license allows Ncardia to commercialize products derived from human induced pluripotent stem cells.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Ncardia competitors and assessment

Company assessment

Direct peers

  • FUJIFILM Cellular Dynamics (CDI): FUJIFILM Cellular Dynamics is the most direct competitor: an iPSC pioneer founded out of Jamie Thomson's lab, offering a comprehensive catalog of iPSC-derived cells (cardiomyocytes, neurons, hepatocytes, etc.) and custom iPSC services. Both companies target the same biopharma preclinical customer with off-the-shelf cell products and drug discovery assay services.
  • Evotec: Evotec is a leading global CRO with established iPSC-based drug discovery platforms (e.g., its PanHunter screening and iPSC-derived disease modeling services). Comparable to Ncardia in offering integrated iPSC-based discovery services to large pharma, but at materially greater scale and with broader therapeutic area coverage.

Broad incumbents

  • Charles River Laboratories: Charles River is a top-3 global CRO with growing iPSC and cell-based assay capabilities across safety, discovery, and manufacturing services. Ncardia's Divisional CEO Jeroen de Groot was previously COO Early Discovery at Charles River, illustrating direct talent and capability overlap. Competes for the same enterprise pharma RFPs.
  • Lonza: Lonza is a global CDMO with significant cell and gene therapy manufacturing capabilities plus iPSC-related services. As the most established cell therapy CDMO, it represents the scaled incumbent that Cellistic (Ncardia's affiliate) is positioning against in the GMP iPSC manufacturing space.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher, via its Patheon acquisition (where Ncardia CEO Jason Conner previously held leadership), operates a global pharma services network including biologics and cell therapy capabilities. Represents the largest scaled competitor that combines CDMO scale with pharma services relationships.

Emerging players

  • bit.bio: bit.bio is an emerging UK-based iPSC platform company offering opti-ox™-engineered iPSC-derived cell products for research and therapeutic applications. Direct competitor in iPSC cell products, particularly neural and immune cell types, with novel reprogramming technology.
  • Axol Bioscience: Axol Bioscience is an emerging UK-based iPSC-derived cell product company specializing in neural and cardiac cell types. Direct catalog overlap with Ncardia's Ncyte® neural cells, though smaller in scale and primarily serving academic and early-stage biotech customers.
  • Pluristyx: Pluristyx is an emerging iPSC technology company offering iPSC banking, gene editing, and differentiation services. Direct peer in custom iPSC services, particularly for cell therapy developers, with comparable focus on supporting translational programs.
  • ReproCELL (now part of Axol Bioscience parent group / Bionova Scientific): ReproCELL is a Japan-based iPSC-derived cell product and services company with strong ties to Kyoto University/Yamanaka's iPSC ecosystem — same licensor as Ncardia. Direct competitor in iPSC catalog products, particularly strong in Asia-Pacific where Ncardia's reach is more limited.

Regional players

  • Cell Signaling Technology (CST): CST's Cell signaling portfolio includes high-quality iPSC-derived cell products and reagents. Comparable in catalog cell product offering, with stronger footprint in US academic and pharma research customers versus Ncardia's European-anchored presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Ncardia social profiles

Digital presence

Ncardia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ncardia leadership team

Management profile

Number of profiles

Profiles8 records

Ncardia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ncardia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ncardia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ncardia

What does Ncardia do?

Ncardia operates an iPSC technology platform that produces and sells standardized, off-the-shelf human iPSC-derived cell products (including ventricular and atrial cardiomyocytes, endothelial cells, astrocytes, microglia, smooth muscle cells, 3D cardiac microtissues, and non-human primate cardiomyocytes) alongside custom iPSC services — reprogramming, proprietary STAR-CRISPR gene editing, large-scale differentiation and iPSC-based assay/screening services for drug discovery, disease modeling, and safety/toxicology assessment. Customers are biopharmaceutical companies, biotechnology companies, cell therapy developers and academic research institutions that need physiologically relevant human cell models for preclinical research and therapeutic development.

Is Ncardia a public or private company?

Ncardia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ncardia founded?

Ncardia was founded in 2017. It employs 11 to 50 people.

Where is Ncardia based?

Ncardia is headquartered in Leiden, Netherlands, in the Europe region.

How does Ncardia make money?

Three revenue lines are on record. iPSC Cell Products (Catalog) is the primary driver. The others are custom iPSC Services and drug Discovery Assay Services.

Who are Ncardia's main competitors?

Direct peers on record are FUJIFILM Cellular Dynamics (CDI) and Evotec. Broad incumbents are Charles River Laboratories, Lonza and Thermo Fisher Scientific (Patheon). Emerging players are bit.bio, Axol Bioscience, Pluristyx and ReproCELL (now part of Axol Bioscience parent group / Bionova Scientific). Cell Signaling Technology (CST) is listed as a regional player.

Does Ncardia have an API?

No public API is recorded for Ncardia.

What industry is Ncardia in?

Ncardia's product category is iPSC Drug Discovery Services & Cell Models. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LumcNew platform to accelerate cardiac drug developmentResearchers at LUMC in the Netherlands have developed an automated platform using stem cell-derived 3D cardiac microtissues to accelerate cardiac drug discovery, in collaboration with biotechnology company Ncardia. The platform, which combines robotics and machine learning, was used to screen over 2,000 FDA-approved compounds and identified approximately 100 that were able to correct abnormal heart rhythms in a model of catecholaminergic polymorphic ventricular tachycardia (CPVT1). The technology aims to bridge the gap between academic research and industrial drug development by providing scalable, human-relevant models for cardiac safety testing and therapeutic discovery.Drug Discovery World (DDW)What comes after animal models?The US Food and Drug Administration (FDA) released a roadmap in April 2025 to reduce animal testing in preclinical safety studies by 2035, promoting New Approach Methodologies (NAMs) such as iPSC models, organ-on-chip platforms, and computational simulations to replace live animal models. The article highlights the escalating costs (cynomolgus monkeys exceeding $19,000 each), supply chain disruptions (inability to meet 66% of research requests since 2021), and ethical concerns driving the need for alternatives. Ncardia executives argue for a hybrid approach combining iPSC-derived models, organ-on-chip systems, AI-driven simulations, and limited in vivo studies to improve human relevance and reduce reliance on non-human primates in drug development.Business Wire BlogNcardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision MedicineNcardia launched Ncyte Heart in a Box, a 3D cardiac microtissue model derived from human induced pluripotent stem cells. The model integrates ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts to replicate human heart complexity. It aims to advance cardiovascular research, drug discovery, and precision medicine.NcardiaCase Study: Enabling tissue engineering through robust process development and manufacturing of key cell types in the lungNcardia's case study details the development of scalable, data-driven procedures for differentiating induced pluripotent stem cells into the four main human lung cell types. The company, which has over a decade of iPSC experience across cardiac, neuronal and endodermal lineages, aims to deliver pure, functional cells for disease modeling, drug discovery, regenerative medicine and tissue engineering.Business Wire BlogNcardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality TodayNcardia launched Cellistic, a business focused on iPSC-based cell therapy development and manufacturing. The company offers scalable cGMP capacity, analytical support, and clinical readiness for allogeneic cell therapies. The launch aims to address challenges in large-scale allogeneic production.FierceBiotechNcardia inks $60M funding deal to expand discovery and commercial production services for stem cellsNcardia secured a $60 million strategic partnership with U.S. investment firm Kiniciti to expand its discovery and commercial production capabilities for human-induced pluripotent stem cells. The funding will be used to enhance good manufacturing practice facilities for cell therapies and build cellular models for drug safety assessment. This deal supports Ncardia's global expansion following its 2017 merger of Pluriomics and Axiogenesis.PR NewswireNcardia Expands iPSC Manufacturing and Phenotypic Drug Discovery Services With Support From InvestorsNcardia, a stem cell drug discovery company, announced the expansion of its iPSC manufacturing and drug discovery services following investor confidence demonstrated through a capital increase. The expansion comes after the company underwent restructuring due to the insolvency of its former German entity (Ncardia AG), with all manufacturing now concentrated at its facility in Gosselies, Belgium and drug discovery operations continuing from its Leiden, Netherlands headquarters. The company is positioning the investment to accelerate capabilities in contract cell manufacturing and assay development for cardiovascular and neurological cell models.FinSMEsNcardia Completed €10.5M Series B FinancingNcardia, a Belgian stem cell technology company, completed a €10.5M Series B financing round led by Épimède. The funds will accelerate international growth, develop safety assays, and expand cardiovascular drug discovery capabilities. The company produces iPSC-derived cell types and assay services for drug testing.Business Wire BlogNcardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent PortfolioRoche and its affiliates obtained a non-exclusive, worldwide license to Ncardia's disease modeling patents covering stem cell-derived cell models. The agreement, with undisclosed financial terms, is the first step in Ncardia's strategy to make its technology available to the pharmaceutical drug discovery and development market.PR NewswireLuxcel Biosciences Ltd Announces World First Physiologically Relevant, In Vitro Ischemia-Reperfusion Model in Conjunction with BMG LABTECH and NcardiaLuxcel Biosciences, BMG LABTECH, and Ncardia announced a first microplate-based in vitro ischemia-reperfusion model combining a CLARIOstar reader, MitoXpress oxygen assay, and iPSC-derived cardiomyocytes. The model enables real-time oxygenation monitoring to study IR injury and reduce reliance on animal models.